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Background: Severe asthma is a heterogeneous disease and the relationship between airway inflammation and
airway remodelling is poorly understood. We sought to define sputum mediator profiles in severe asthmatics
categorised by CT-determined airway geometry and sputum differential cell counts.
Methods: In a single centre cross-sectional observational study we recruited 59 subjects with severe asthma that
underwent sputum induction and thoracic CT. Quantitative CT analysis of the apical segment of the right upper
lobe (RB1) was performed. Forty-one mediators in sputum samples were measured of which 21 mediators that
were assessable in >50% of samples were included in the analyses.
Results: Independent of airway geometry, sputum MMP9 and IL-1β were elevated in those groups with a high
sputum neutrophil count while sputum ICAM was elevated in those subjects with a low sputum neutrophil count.
In contrast, sputum CCL11, IL-1α and fibrinogen were different in groups stratified by both sputum neutrophil
count and airway geometry. Sputum CCL11 concentration was elevated in subjects with a low sputum neutrophil
count and high luminal and total RB1 area, whereas sputum IL1α was increased in subjects with a high sputum
neutrophil count and low total RB1 area. Sputum fibrinogen was elevated in those subjects with RB1 luminal
narrowing and in those subjects with neutrophilic inflammation without luminal narrowing.
Conclusions: We have demonstrated that sputum mediator profiling reveals a number of associations with airway
geometry. Whether these findings reflect important biological phenotypes that might inform stratified medicine
approaches requires further investigation.
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Asthma affects up to 5% of the adult population and ap-
proximately 10% of asthmatics have severe or refractory
disease [1,2]. This group represents an unmet need as
they consume a disproportionate amount of healthcare
resources, and contribute to the mortality and morbidity
of the disease. Severe asthma is a complex disease with
phenotypic heterogeneity in terms of the pattern and
intensity of airway inflammation and remodelling and
clinical expression of disease [3]. Understanding the* Correspondence: ceb17@le.ac.uk
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reproduction in any medium, provided the orunderlying pathobiology of severe asthma phenotypes
mainly those with Th2 high [4] or eosinophilic airway in-
flammation [5] has translated into recent success with
anti IL-5 [6] and anti IL-13 therapy [7,8]. In particular,
anti-IL5 led to improvements in exacerbation frequency
and airway remodelling in terms of sub-epithelial matrix
deposition and airway wall geometry determined by CT
analysis [6]. Understanding the relationship between the
inflammatory profile in the airway and airway geometry
may help to identify patient phenotypes that may be
more amenable to strategies to modulate airway remod-
elling and might prioritise potential targets within strati-
fied populations for specific highly targeted therapies.
We and others have used quantitative and qualitative
CT image analysis to define the airway geometry in
asthma [9-11]. In a previous report, we found thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with neutrophilic inflammation and airflow
obstruction but was poorly associated with patient
reported outcomes [10]. This association between per-
sistent neutrophilic inflammation and lung function de-
cline is a consistent observation in asthma and COPD
[12,13]. Sputum and bronchoalveolar lavage cytokine
profiling by analyses of protein and transcriptomics in
asthma and chronic obstructive pulmonary disease has
demonstrated that patterns of inflammatory mediators
are associated with cellular profiles and clinical out-
comes [14-17]. We hypothesised that there is differential
sputum mediator profiles in severe asthmatics stratified
by airway geometry determined by CT analysis. To test
our hypothesis we measured sputum mediators in
patients that had undergone CT analysis and i) dichoto-
mised subjects by the median right upper lobe apical
bronchus (RB1) luminal area or the median RB1 total
area and ii) stratified by the median sputum neutrophil
count and airway geometry.
Methods
Subjects
We performed a single centre retrospective cross-
sectional study based upon the difficult asthma clinic
(DAC) at Glenfield Hospital, Leicester, UK. Fifty-nine
subjects out of the 92 included in a previous quantitative
CT analysis between 2004 to 2008 were included in this
study if they had adequate sputum samples for mediator
analysis (>150 μL supernatant volume). Sputum was
obtained at the routine clinical visit immediately before
or after the CT scan. All assessments were undertaken at
stable visits at least 2 months after a severe exacerbation.
Subjects attending DAC undergo an extensive re-
evaluation, as part of their routine clinical care including
an extensive history, skin prick tests for common aeroal-
lergens, spirometry, methacholine challenge tests, spu-
tum induction [18] and asthma control questionnaire
(ACQ6) [19]. A history of severe exacerbations was
defined as worsening of symptoms requiring ≥3 days of
high dose systemic corticosteroids [20]. The diagnosis of
asthma is confirmed by a respiratory physician based on
history and one or more of the following objective cri-
teria (maximum diurnal peak expiratory flow variability
>20% over a 2 week period, significant bronchodilator
reversibility defined as an increase in FEV1 of >200mls
post bronchodilator or a PC20 methacholine of <8 mg/
ml). Severe asthma was defined in accordance with the
American Thoracic Society (ATS) workshop on refrac-
tory asthma [21]. Informed consent for clinical charac-
terisation and computed tomography was obtained from
all subjects and the study was approved by the Leicester-
shire, Northamptonshire and Rutland Research Ethics
Committee.Cross sectional imaging
HRCT was performed using Siemens Sensation 16 scan-
ner. Scans were acquired using standard HRCT protocol
(sequential scanning at 10-mm increments with 1-mm
collimation) from the apex of the lung to the diaphragm
[10]. Patients were scanned in the supine position at
maximal inspiration (adequate breath holding rehearsed
prior to scan), with their arms held over their heads.
Images were reconstructed using a high spatial fre-
quency algorithm, through a 512X512 matrix, with a
small field of view targeted to image only pulmonary
areas. Scanning time ranged from 30-45 s with a voltage
of 120kVp and peak effective tube current (dose modu-
lation based on size and attenuation profile of the region
scanned used to minimise radiation dose) of 140 mAs
(range 65-140 mAs).Qualitative and quantitative airway analysis
CT scans were analysed qualitatively by a single observer
and the presence or absence of bronchiectasis and/or
bronchial wall thickening was reported as described pre-
viously [9]. An automated program Emphylyx-J V
1.00.01 [22,23] using the full-width at half-maximum
(FWHM) technique was used to determine the airway
cross-sectional geometry. Image data were transferred
from the CT workstation to a personal computer in
DICOM 3.0 format. After identifying the RB1 the oper-
ator placed a seed point in the airway lumen from which
64–128 rays were cast across the airway wall. The
boundaries of the wall were defined by the midpoint of
the profile of CT numbers across each ray. Lumen Area
(LA), wall area (WA), maximum and minimum airway
diameter were measured. High spatial frequency algo-
rithm was used for reconstruction of images as it results
in reduced blurring and, as demonstrated by phantom
studies, [24] is associated with reduced errors in airway
wall estimation using FWHM method. Correction equa-
tions for both size dependant error using the FWHM
method and oblique orientation of airways were applied
as previously described [10] LA and WA were corrected
for body surface area (BSA). Total area (TA) and per-
centage WA (%WA) were derived from LA and WA
(TA = LA +WA; %WA =WA/TA x100).
Sputum processing and cytokine assessment
The sputum was selected, dispersed using mucolytic
dithiothreitol, and processed to generate a sputum dif-
ferential cell count and cell-free supernatants [25,26]
Measurements for validated mediators were measured
using multiplex assays from Myraid RBM (Austin, TX,
USA). We included mediators that have been previously
validated in sputum and were measurable in >50% of
samples. The full list of mediators is as shown Table 1.
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Statistical analysis was performed using PRISM version
4 (GraphPad Software, San Diego, CA), SAS version 8.02
(SAS Institute Inc. Cary, NC) and SPSS version 16
(SPSS, Inc. Chicago, IL). Parametric and non-parametric
data are presented as mean (standard error of the mean)
and median (interquartile range) respectively. Subjects
were dichotomised into high and low luminal area, total
area and wall area using the median values as the cut-
offs (RB1 luminal area LA/BSA (≤5 mm2/m2 versus
>5 mm2/m2) or total area TA/BSA (≤16 mm2/m2 versus
>16 mm2/m2) or wall area WA/BSA (≤11.5 mm2/m2 ver-
sus >11.5 mm2/m2). Between group differences were
analysed by unpaired t-tests and Mann–Whitney tests as
appropriate. Spearman correlation coefficient was used
to determine the relationship between RB1 dimensions
(LA/BSA, WA/BSA, TA/BSA and %WA) and clinical in-
dices and sputum mediator data. Our previous study
highlighted the relationship between CT-determined re-
modelling and neutrophilic inflammation [10]. There-
fore, we further stratified the population into four
groups using the medians as cut-offs for the differential
sputum neutrophil counts (≤66% versus >66%) and the
RB1 total area or luminal area. Comparisons across
groups were made by Kruskal-Wallis test with post hocTable 1 Mediators measured in sputum samples




Intercellular Adhesion Molecule 1 (ICAM-1)
Interleukin-1 alpha (IL-1 alpha)
Interleukin-1 beta (IL-1 beta)





Monocyte Chemotactic Protein 1 (CCL2)




Tissue Inhibitor of Metalloproteinase 1 (TIMP-1)
Tumor Necrosis Factor alpha (TNF-alpha)
Tumor Necrosis Factor Receptor 2 (TNFR2)
Vascular Cell Adhesion Molecule-1 (VCAM-1)
Vascular Endothelial Growth Factor (VEGF)Dunn’s pair-wise comparisons. A p value of <0.05 was
taken as statistically significant.
Results
The clinical and CT imaging characteristics and sputum
mediator concentrations for the whole population and
dichotomised by the median RB1 total and luminal areas
are as shown (Tables 2 and 3). Subjects with a low total
area and luminal area were older with a later age of
onset of disease, higher body mass index, more bronchi-
ectasis and more frequent exacerbations (Table 2). There
was marked heterogeneity in mediator concentrations
within and between the groups of subjects and only the
sputum CCL11 concentration was significantly different
in the groups stratified by median RB1 total area ([48.3
versus 76.3 pg/ml], p = 0.026). Further differences were
observed between subjects stratified by RB1 luminal area
(Figure 1, Table 3) for sputum CCL11 ([49.1 versus
74.9 pg/ml], p = 0.043), IL-1α ([38 versus 19 pg/ml],
p = 0.043) and CCL4 ([349 versus 611 pg/ml] p = 0.036).
RB1 luminal area correlated with sputum CCL11
(r = 0.31, p = 0.03) but there were no significant correla-
tions between RB1 total or luminal area and other
mediators. There were no differences in cytokine con-
centrations between those with high or low wall area.Not measurable in >50 % of samples, excluded
Brain-Derived Neurotrophic Factor (BDNF)
C-Reactive Protein (CRP)









Interleukin-12 Subunit p70 (IL-12p70)
Interleukin-12 Subunit p40 (IL-12p40)
Interleukin-23 (IL-23)
Macrophage Inflammatory Protein-1 alpha (CCL-3)
Matrix Metalloproteinase-2 (MMP-2)
Stem Cell Factor (SCF)
T-Cell-Specific Protein (CCL-5)
Tumor Necrosis Factor β (TNF-β)
von Willebrand Factor (vWF)













N 59 30 29 30 29
Male, n 25 12 13 0.37 12 13 0.37
Current age 49 (2) 53 (2) 45 (2) 0.02 53 (2) 45 (2) 0.024
Age of onset 28 (2.5) 34 (3.5) 21 (3) 0.037 32(3.5) 22 (3) 0.041
BMI, kg/m2 29.8 (0.8) 32.3 (1.2) 27.4(1.1) 0.003 32.6 (1.1) 27.1 (1.1) 0.001
Habitual smokers and ex smokers with
>10 py
13 10 3 0.16 9 4 0.3
Pack years history 8 (2.5) 11 (5) 6 (2.5) 0.36 11 (5) 6 (2.5) 0.23
Severe Exacerbations 2 2 (0.3) 3 (0.4) 0.03 2 (0.3) 3 (0.4) 0.03
IgE 153 [97–241] 145 [74–183] 162 [84–313] 0.87 143 [82–325] 167 [76–270] 0.89
ACQ6 2.18 (0.13) 2.2 (0.17) 2.14 (0.23) 0.74 2.21 (0.17) 2.15 (0.23) 0.76






0.28 2000 [400–4000] 2000 [640–4000] 0.43
Subjects taking oral corticosteroids 25 15 10 0.72 15 10 0.72
Daily prednisolone dose, mg 4.5 (0.7) 6 (1.2) 2.5 (0.7) 0.54 5.5 (1.5) 3.5 (0.8) 0.83
Pre Bronchodilator FEV1 2.26 (0.12) 2.24 (0.17) 2.2 (0.16) 0.9 2.18 (0.17) 2.34 (0.15) 0.49
Pre Bronchodilator FEV1% predicted 2.42 (0.12) 2.4 (0.18) 2.4 (0.16) 0.98 2.33 (0.18) 2.5 (0.15) 0.48
BD reversibility, ml 0.23 (0.07) 0.31 (0.14) 0.13 (0.03) 0.23 0.29 (0.13) 0.15 (0.03) 0.36
Pre Bronchodilator FVC 3.26 (0.1) 3.22 (0.21) 3.29 (0.20) 0.87 3.1 (0.22) 3.3 (0.18) 0.39
Pre Bronchodilator FVC 3.35 (0.1) 3.36 (0.21) 3.32 (0.20) 0.88 3.27 (0.21) 3.42 (0.18) 0.61
Pre Bronchodilator FEV1% of predicted 75.2 (3) 76 (4) 74.3 (3.6) 0.79 74.3 (5) 76 (3.4) 0.77
Post Bronchodilator FEV1% of predicted 80.8 (2.9) 80.8 (4) 80.8 (3.4) 0.99 78.4 (5) 83.1(3.2) 0.42
Bronchodilator Reversibility %FEV1 5.9 (0.97) 5.4 (1.4) 6.4 (1.7) 0.58 4.7 (0.8) 7.1 (1.7) 0.22
Pre Bronchodilator FEV1/FVC ratio 69.5 (1.8) 69 (2.6) 69.3 (2.7) 0.82 69.6 (2.4 69.4 (2.5) 0.95
Post Bronchodilator FEV1/FVC ratio 72.1 (1.7) 78 (2.5) 72.8 (2.5) 0.62 70.7 (2.4) 73.4 (2.4) 0.44
Total Cells 0.5 [0.4-0.8] 0.6 [0.3-1.1] 0.5 [0.3-0.8] 0.61 0.6 [0.3-1] 0.5 [0.3-0.8] 0.77
Neutrophils % 58.3 [48–69.5] 55.6 [40.7-76.3] 60 [50.1-72.6] 0.97 56.2 [47–77] 59.9 [49.5-72.5] 0.76
Eosinophils % 2.2 [1.5-3.4] 2.5 [1.3-4.5] 2 [1.1-3.7] 0.43 2.2 [1.1-4.2] 2.2 [1.2-4] 0.80
Bronchiectasis present,% 23 (39) 7(30) 16 (69) 0.02 9 (39) 14 (60) 0.16
Bronchial Wall Thickening present,% 39 (67) 21(53) 18 (46) 0.66 22 (56) 17 (43) 0.22
Lumen area/Body Surface Area (mm2/m2) 5.3 (0.3) 3.4 (0.2) 7.2 (0.42) 0.001 3.2 (0.2) 7.3 (0.4) 0.001
Total area/Body Surface Area (mm2/m2) 17.8 (0.8) 12.7 (0.6) 22.8 (1) 0.001 13.2 (0.8) 22.3 (0.9) 0.001
Desai et al. Respiratory Research 2013, 14:17 Page 4 of 13
http://respiratory-research.com/content/14/1/17We further stratified the population by the sputum
neutrophil count as we had previously reported relation-
ships between CT parameters and neutrophilic inflam-
mation. The clinical and CT imaging characteristics and
sputum mediator concentrations for subjects stratified
by differential sputum neutrophil count and the median
RB1 total and luminal areas are as shown (Tables 4, 5, 6, 7).
Subjects in the high neutrophil, high RB1 total or lu-
minal area groups had significantly the highest number
of severe exacerbations in the previous year and the
highest proportion of subjects with qualitative CT evi-
dence of bronchiectasis. Those in the low neutrophil
and high RB1 total or luminal area groups hadsignificantly the lowest body mass index (BMI). No
other significant differences in clinical characteristics
were observed (Tables 4 and 6).
The patterns in sputum mediator concentrations were
very different between these groups. The sputum CCL11
concentration was elevated in those with a low neutro-
phil count and either a high RB1 total (p = 0.005) or lu-
minal area (p = 0.004) (Figures 2 and 3). Reciprocally,
these were the groups with the lowest sputum fibrinogen
concentrations (p = 0.002 and p = 0.013 respectively).
Similarly, sputum MMP9 was decreased in the low neu-
trophil group with high RB1 luminal area. Sputum
ICAM was elevated in the groups with a low neutrophil
Table 3 Sputum mediator concentrations for subjects stratified by the median RB1 total area and luminal area
Total Low total area High total area p value Low luminal area High luminal area p value
Factor VII* 2.15 [1.89-2.43] 2.03 [1.69-2.44] 2.27 [1.89-2.72] 0.40 2.01 [1.68-2.41] 2.30 [1.91-2.77] 0.25
Fibrinogen* 240 [172–335] 260 [161–421] 223 [137–364] 0.48 291 [184–461] 200 [121–330] 0.16
Ferritin* 2.21 [1.54-3.17] 2.56 [1.62-4.06] 1.94 [1.10-3.42] 0.38 2.21 [1.35-3.61] 2.21 [1.27-3.85] 0.9
IL-1 α 27 [19-37] 35 [23–54] 20 [12-33] 0.13 38 [25–58] 19 [12-30] 0.041
IL-1 β 47 [31–71] 44 [26–76] 49 [25–96] 0.40 45.4 [26.72-77.14] 48.8 [25–95.4] 0.40
IL-1RA 6951 [5168–9350] 8147 [5120–12964] 5962 [4033–8815] 0.59 9108 [5752–14421] 5353 [3662–7824] 0.19
IL-6 41 [30–56] 32 [20–53] 52 [35–76] 0.14 33.3 [20.5-54.1] 51.8 [35.3-76.1] 0.16
IL-8 3608 [2462–5287] 2846 [1599–5064] 4537 [2686–7665] 0.37 3062 [1790–5237] 4227 [2393–7469] 0.43
IL-15 440 [370–520] 410 [320–540] 460 [360–600] 0.60 410 [320–540] 460 [360–600] 0.60
IL-18 40.2 [32.2-50.2] 37.2 [27–51.3] 43.3 [31.2-6] 0.31 39.2 [27.7-55.5] 41.2 [30.5-55.6] 0.53
TNF-α 6.46 [4.58-9.12] 4.66 [3.45-7.30] 9.35 [3.91-17.8] 0.09 4.71 [3.48-6.36] 9.25 [4.84-17.6] 0.06
TNFR2 330 [230–490] 280 [160–510] 390 [220–670] 0.46 290 [160–500] 390 [220–680] 0.39
CCL2 100 [75–134] 96 [62–150] 105 [71–156] 0.35 100 [65–153] 101 [67–153] 0.98
CCL4 462 [313–682] 380 [241–600] 554 [291–1052] 0.42 349 [220–555] 611 [322–1158] 0.036
CCL11 59.8 [48.4-73.9] 48.3 [39.2-59.6] 76.3 [52.4-111] 0.026 49.1 [39.7-60.7] 74.9 [51.3-109] 0.043
MMP-3* 0.25 [0.19-0.33] 0.27 [0.18-0.40] 0.23 [0.16-0.33] 0.51 0.26 [0.18-0.39] 0.24 [0.16-0.34] 0.56
MMP-9* 38.1 [26.7-54.3] 48.8 [29.1-81.8] 30.3 [18.3-50] 0.11 50.8 [31.6-81.7] 29.1 [17.1-49.5] 0.09
TIMP-1* 108 [78.6-14] 93 [56–155] 124 [82–188] 0.33 98 [60–159] 118 [75–185] 0.40
ICAM-1 2900 [2170–3870] 2490 [1650–3740] 3370 [2200–5150] 0.32 2400 [1620–3550] 3530 [2280–5460] 0.19
VCAM-1 1130 [850–1490] 1240 [830–1860] 1003 [690–1560] 0.80 1200 [820–1760] 1060 [690–1630] 0.78
VEGF 837 [678–1033] 793 [592–1061] 882 [640–1214] 0.51 823 [617–1098] 851 [616–1175] 0.83
All units are pg/ml except *denoting ng/ml, data represented as Geometric mean [95% CI].
Figure 1 A) Subjects stratified by low or high RB1 total area on the X axis, their corresponding sputum CCL11 levels (pg/ml) on the
log transformed Y axis. Bar represents median value, p value by Mann Whitney U test, and subjects stratified by low or high RB1 luminal area
on the X axis, their corresponding B) sputum CCL11 (pg/ml), C) sputum IL-1α (pg/ml) and D) sputum CCL4 (pg/ml) on the log transformed Y
axis. Bar represents median value, p value by Mann Whitney U test.
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N 14 15 13 17
Male, n 5 9 3 8 0.24
Current age 52 (3) 54 (3) 44 (4) 47 (3) 0.15
Age of onset 36 (5) 31 (5) 24 (5) 20 (4) 0.08
BMI, kg/m2 32.7 (1.6) 32 (2) 24.4 (1.4) 29.7 (0.8) 0.002
Habitual and ex smokers with >10
pack year history
4 5 2 2 0.95
Pack years history 6.5 (3) 14.5 (9) 7 (4) 5 (3) 0.59
Severe Exacerbations 1.5 (0.5) 2.5 (0.4) 2.5 (0.6) 4 (0.6) 0.01
IgE 208 221 270 119 0.28
ACQ6 2.2 (0.25) 2.2 (0.26) 1.9 (0.31) 2.3 (0.27) 0.68
Subjects taking oral corticosteroids,
n
7 8 4 6 0.87
Daily Predinsolone dose, mg 6 (1.9) 5.5 (1.6) 3 (1.5) 2 (0.7) 0.14
Pre Bronchodilator FEV1 2.21 (0.3) 2.29 (0.2) 2.24 (0.2) 2.31 (0.25) 0.99
Post Bronchodilator FEV1 2.36 (0.3) 2.48 (0.2) 2.41 (0.2) 2.42 (0.25) 0.98
Bronchodilatorreversibility, mls 0.15 (0.03) 0.46 (0.2) 0.17 (0.06) 0.11 (0.04) 0.28
Pre Bronchodilator FVC 3.12 (0.3) 3.31 (0.2) 3.33 (0.2) 3.26 (0.32) 0.96
Post Bronchodilator FVC 3.24 (0.3) 3.49 (0.2) 3.39 (0.2) 3.28 (0.32) 0.92
Pre Bronchodilator FEV1 % of
predicted
74.4 (8.2) 77.6 (5.6) 76.7 (4.9) 74.1 0.93
Post Bronchodilator FEV1 % of
predicted
79.4 (7.8) 82.1 (6.2) 83.4 (4.3) 83.8 0.94
Bronchodilator Reversibility % FEV1 5.03 (1.1) 5.8 (1.3) 6.7 (1.9) 5.5 (1.6) 0.94
Pre Bronchodilator FEV1/FVC ratio 69.8 (4.1) 69.8 (3.5) 68 (3.3) 70.3 (4.1) 0.97
Post Bronchodilator BD FEV1/FVC
ratio
72.1 (4) 70.7 (3.1) 72.9 73.2 (4) 0.96
Total Cells 0.53 [0.2-1.43] 0.7 [0.41-1.4] 0.31 [0.15-0.63] 0.82 [0.4-1.4] 0.79
Neutrophils % 35 [19.6-62.5] 86 [80.5-91.9] 39.5 [29.5-52.5] 83.8 [78.4-88.6] <0.001
Eosinophils % 2.8 [1.1-7] 2.2 [0.9-9.3] 3.7 [1.4-10.8] 1.2 [0.2-2.7] 0.16
Bronchiectasis present n (%) 2 (14) 5 (33) 5 (38) 11 (65) 0.03
Bronchial Wall Thickening present 10 (70) 11 (73) 8 (62) 10 (63) 0.87
Lumen area/Body Surface Area
(mm2/m2)
3.6 (0.26) 3.3 (0.35) 7.1 (0.66) 7.2 (0.58) <0.001
Total area/Body Surface Area (mm2/m2) 13.3 (0.54) 12.1 (0.67) 21.8 (1.64) 23.6 (1.27) <0.001
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minal area whereas in contrast sputum IL-1β was ele-
vated in those with a high neutrophil count irrespective
of airway geometry. Sputum IL-1α was markedly
increased in those with a high neutrophil count and a
low RB1 total area (p < 0.001) (Figure 2).
Similar differences between groups were observed if
patients were stratified by sputum eosinophil count
(≤3% versus >3%) and median RB1 total and luminal
areas with sputum CCL11 concentration greatest in
those subjects with elevated sputum eosinophil countand high RB1 total or lumen area and in the same group
the lowest sputum fibrinogen, and IL-1α concentrations
(data not shown).
Discussion
We report here differential sputum mediator profiles be-
tween groups of severe asthmatic patients stratified by
airway wall geometry, with more marked differences be-
tween groups when patients were stratified further by
sputum neutrophil counts. Some of the differences were
closely related to the differential sputum cell counts
Table 5 Sputum mediator concentrations for subjects stratified by the median neutrophil count (%) and RB1 total area
Low neutrophil, Low total
area
High neutrophil, Low total
area
Low neutrophil, High total
area




Factor VII* 2.19 [1.59-3.01] 1.88 [1.5-2.37] 2.06 [1.51-2.83] 2.41 [1.89-3.07] 0.61
Fibrinogen* 271 [165–442] 249 [103–602] 94 [60–148] 430 [220–830] 0.002
Ferritin* 2.28 [1.06-4.88] 2.93 [1.63-5.26] 1.74 [0.99-3.07] 2.11 [0.79-5.66] 0.5
IL-1 α 38 [18–79] 43 [29–64] 13 [7–24] 28 [14–58] 0.001
IL-1 β 34.6 [17.4-69] 56.6 [23.7-135] 15.8 [8.87-28.2] 117 [47–290] 0.005
IL-1RA 8249 [3792–17942] 8053 [4281–15148] 4341 [2370–7952] 7599 [4441–13002] 0.39
IL-6 40.7 [20.1-82.6] 26.1 [12.3-55.5] 41 [23.3-72.3] 62.7 [35.1-112] 0.27
IL-8 3469 [1790–6726] 2365 [865–6646] 3857 [2088–7124] 5138 [2186–12076] 0.54
IL-15 390 [260–600] 430 [290–670] 410 [250–670] 500 [360–700] 0.43
IL-18 35 [22–57] 38 [23–64] 34.7 [22.6-53.5] 50.3 [30.8-82] 0.32
TNF-α 4.64 [3.47-6.2] 4.7 [2.21-9.99] 5.8 [3.74-9] 10.5 [4.67-23.7] 0.07
TNFR2 340 [140–830] 240 [100–560] 240 [130–460] 540 [230–1230] 0.54
CCL2 153 [92–256] 62.2 [31–124] 104 [53–205] 10 6[62–181] 0.079
CCL4 380 [225–640] 380 [165–877] 866 [299–2508] 414 [174–983] 0.096
CCL11 56 [39.5-79.4] 41.2 [32.3-52.4] 137 [72–261] 54.6 [36.1-82.5] 0.0047
MMP-3* 0.29 [0.14-0.57] 0.25 [0.14-0.42] 0.20 [0.11-0.36] 0.26 [0.16-0.43] 0.58
MMP-9* 41.3 [15.5-110] 55.7 [29.9-103] 11.6 [7.16-19] 65.8 [36–120] 0.17
TIMP-1* 153 [104–225] 58 [23–145] 139 [74–226] 114 [62–210] 0.25
ICAM-1 4050 [2250–7280] 1520 [930–2510] 4800 [2220–10600] 2600 [1570–4320] 0.017
VCAM-1 1400 [690–2820] 1080 [670–1750] 1020 [440–2350] 1040 [670–1630] 0.47
VEGF 1109 [799–1539] 579 [370–907] 903 [551–1481] 865 [542–1381] 0.061
All units are pg/ml except *denoting ng/ml, data represented as Geometric mean [95% CI].
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http://respiratory-research.com/content/14/1/17such as sputum MMP9 and IL-1β, which were elevated
in those groups with a high neutrophil count and spu-
tum ICAM-1 was elevated in those subjects with a low
sputum neutrophil count independent of airway geom-
etry [27]. However, other differences were observed that
were dependent upon both stratification by the sputum
neutrophil count and airway geometry namely CCL11,
IL-1α and fibrinogen. Sputum CCL11 concentration was
elevated in subjects with a low sputum neutrophil count
and high luminal and total area, whereas sputum IL1α
was increased in subjects with a high sputum neutrophil
count and low total area. Sputum fibrinogen was ele-
vated in those subjects with luminal narrowing inde-
pendent of sputum cellular differential, but was also
increased in subjects with neutrophilic inflammation
without luminal narrowing. These findings support the
view that there are differential sputum mediator profiles
related to airway geometry.
Several sputum mediators were associated more with
neutrophilic inflammation than the pattern of airway
geometry. Two of these mediators IL-1β and MMP-9 are
observed in subjects with COPD and are reported to be
associated with airway bacterial colonisation and neutro-
philic inflammation. Interestingly, Matsumoto et al.
observed an inverse relationship between sputum MMP-9 and%WA which was consistent with our observation
of a low MMP-9 in the high luminal area, non-
neutrophilic group. In contrast, sputum MMP9 was ele-
vated in our study in those with neutrophilic inflamma-
tion independent of luminal area [28]. IL-1β and MMP-
9 promote subepithelial fibrosis, subepithelial collagen
deposition and elastin fibre disruption in asthma and in
COPD are associated with many of the histopathological
features of emphysema [29-32]. This may suggest a
phenotype of remodelling associated more with ‘scaffold
destruction’ leading to airway dilatation from loss of air-
way wall integrity as opposed to a predominant airway
thickening. Indeed, the group with high total and lu-
minal area were associated with increased qualitative
evidence of bronchiectasis and frequent exacerbations.
Although this process has relevance to those subjects
with luminal dilatation, these mediators were also
increased in subjects with neutrophilic inflammation
and luminal narrowing. This suggests either that in these
subjects an alternative inflammatory process is driving
the airway narrowing or that there were changes that oc-
curred earlier in the lung development of these subjects
that led to either airway narrowing in early development
or a predisposition to airway narrowing in the natural
history of the disease.











N 13 16 14 16
Male 4 10 4 7 0.22
Current age 52 (3) 54 (3) 44 (3) 46 (3) 0.14
Age of onset 35 (4) 31 (4) 25 (4) 20 (4) 0.16
BMI, kg/m2 32.8 (1.7) 32.4 (1.8) 24.9 (1.4) 29.1 (0.8) <0.001
Habitual smokers and ex
smokers with >10 py
4 6 2 1 0.86
Pack years history 7 (3) 15 (8) 6.5 (4) 4 (3) 0.48
Severe Exacerbations 1.5 2 2 4 0.05
IgE 266 212 174 141 0.38
ACQ6 2.11 (0.24) 2.29 (0.24) 1.98 (0.30) 2.29 (0.28) 0.82
Subjects taking oral
corticosteroids
7 7 4 7 0.84
Daily predinosolone dose, mg 6.9 (2) 3.9 (1.2) 3.0 (1.4) 3.4 (1.3) 0.30
Pre Bronchodilator FEV1 2.15 (0.32) 2.21 (0.2) 2.29 (0.19) 2.39 (0.25) 0.90
Pre Bronchodilator FEV1 %
predicted
2.29 (0.31) 2.37 (0.22) 2.47 (0.2) 2.53 (0.24) 0.90
Bronchodilator reversibility, ml 0.14 (0.02) 0.42 (0.25) 0.18 (0.05) 0.14 (0.04) 0.44
Pre Bronchodilator FVC 3.07 (0.37) 3.18 (0.27) 3.37 (0.2) 3.40 (0.31) 0.84
Pre Bronchodilator FVC 3.17 (0.37) 3.36 (0.28) 3.44 (0.2) 3.41 (0.31) 0.92
Pre Bronchodilator FEV1 % of
predicted
74.8 (8.9) 73.9 (5.7) 76.1 (4.5) 75.9 (5.3) 0.99
Post Bronchodilator FEV1 % of
predicted
79.7 (8.4) 77.4 (6.2) 82.8 (4) 83.4 (4.9) 0.87
BD Bronchodilator Reversibility
% FEV1
4.8 (1.1) 4.7 (1.1) 6.7 (1.8) 7.4 (2.8) 0.68
Pre Bronchodilator FEV1/FVC
ratio
69.2 (4.4) 70 (3.3) 68.7 (3.2) 70.1 (4.3) 0.99
Post Bronchodilator FEV1/FVC
ratio
71.4 (4.3) 70.1 (2.8) 72.9 (2.8) 74 (4.2) 0.87
Total Cells 0.45 [0.16-1.2] 0.80 [0.45-1.4] 0.37 [0.17-0.80] 0.8 [0.4-1.5] 0.74
Neutrophils % 33.6 [18–62.7] 85.2 [79–91.1] 40.7 [30.9-53.6] 83.9 [78.9-89.6] <0.001
Eosinophils % 2.7 [1–7.4] 1.9 [0.7-4.5] 3.7 [1.5-9.3] 1.4 [0.6-3.2] 0.32
Bronchiectasis present 2 (15) 7 (44) 5 (36) 9 (60) 0.15
Bronchial Wall Thickening
present
10 (77) 12 (75) 8 (57) 9 (60) 0.59
Lumen area/Body Surface Area
(mm2/m2)
3.4 (0.2) 3.1 (0.2) 7.0 (0.6) 7.6 (0.4) <0.001
Total area/Body Surface Area
(mm2/m2)
13.1 (0.5) 13.31 (1.1) 21.3 (1.5) 23.1 (1.4) <0.001
Desai et al. Respiratory Research 2013, 14:17 Page 8 of 13
http://respiratory-research.com/content/14/1/17Fibrinogen was also elevated predominately in those
with neutrophilic inflammation, but was increased in
subjects without neutrophilic inflammation with luminal
narrowing and low RB1 total area. Fibrinogen is an acute
phase soluble plasma glycoprotein, synthesised primarily
in the liver and converted by thrombin into fibrin during
blood coagulation. It is emerging as a promising sys-
temic biomarker in COPD that shows relationships withdisease severity, progression and mortality [33]. There
are studies that link its presence to microvascular leak-
age from plasma exudation, which occurs during remod-
elling or neurogenic inflammation in asthma [34,35] and
may contribute to pathophysiological features of airway
hyperresponsiveness [36]. Fibrinogen leakage exudes into
the extravascular compartment and interacts with
neutrophils causing their sequential activation and












Factor VII* 2.23 [1.58-3.16] 1.85 [1.51-2.26] 2.03 [1.53-2.69] 2.54 [1.95-3.31] 0.36
Fibrinogen* 270 [160–460] 306 [141–662] 101 [65–157] 363 [166–793] 0.037
Ferritin 2280 [990–5220] 2150 [1100–4200] 1780 [1050–2990] 2750 [950–7900] 0.6
IL-1 α 43 [20–90] 34 [19–61] 13 [7–23] 26 [12–54] 0.14
IL-1 β 34.3 [16.2-72.6] 57 [25.1-127] 17 [9.81-29.4] 121 [45.8-323] 0.005
IL-1RA 9021 [3972–20484] 9180 [5058–16662] 4183 [2386–7332] 6642 [3826–11532] 0.054
IL-6 40.5 [18.5-88.7] 28.5 [14.2-57.2] 41.2 [24.6-68.9] 65.3 [35.3-120] 0.20
IL-8 3567 [1739–7316] 2705 [1155–6335] 3730 [2114–6581] 4716 [1710–13009] 0.49
IL-15 400 [250–640] 420 [290–610] 409 [269–623] 520 [360–740] 0.54
IL-18 37.3 [22.5-61.9] 41.1 [23.9-70.6] 33.4 [22.5-49.8] 49.2 [30.8-78.7] 0.19
TNF-α 4.62 [3.32-6.43] 4.81 [2.55-9.05] 5.53 [4.2-7.28] 11.1 [4.58-27.1] 0.19
TNFR2 350 [130–920] 250 [120–510] 250 [140–440] 550 [210–1410] 0.59
CCL2 158 [91–275] 69.1 [37.4-127] 104 [56.3-194] 98.7 [52.7-184] 0.38
CCL4 357 [205–621] 343 [159–742] 861 [330–2245] 464 [181–1189] 0.10
CCL11 56.7 [38.8-83.1] 43 [33.8-54.6] 122 [65.9-226] 53.4 [34.2-83.6] 0.013
MMP-3* 0.30 [0.14-0.62] 0.24 [0.15-0.38] 0.20 [0.12-0.34] 0.27 [0.16-0.47] 0.49
MMP-9* 37 [13–106] 63.2 [40.1-99.5] 13.9 [7.73-25] 58.2 [27.3-124] 0.0015
TIMP-1* 163 [110–241] 65 [29–145] 132 [73.5-239] 107 [51.7-221] 0.14
ICAM-1 3960 [2100–7493] 1600 [1030–2490] 4890 [2400–9970] 2660 [1500–4720] 0.017
VCAM-1 1270 [617–2620] 1140 [734–1790] 1140 [510–2560] 990 [610–1580] 0.54
VEGF 1192 [871–1632] 609 [398–932] 857 [537–136] 845[512–1393] 0.14
All units are pg/ml except *denoting ng/ml, data represented as Geometric mean [95% CI].
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http://respiratory-research.com/content/14/1/17promoting their survival by reducing apoptosis [37].
Sputum fibrinogen is therefore likely to be increased in
subjects with airway wall oedema, which may contribute
to the luminal narrowing in subjects independent of spu-
tum cell differential. Interestingly, it was not increased in
subjects without a sputum neutrophilia and without high
RB1 suggesting that in this group airway wall oedema and
increased vascularity may not play a prominent role. This
needs to be confirmed by examination of the bronchial
wall in this group of subjects. Intriguingly, this group also
had elevated sputum CCL11 and the highest sputum eo-
sinophil count, albeit non-significant, suggesting that al-
though eosinophilic inflammation may be important in
driving remodelling and luminal narrowing in some sub-
jects it is also associated with normal airway geometry.
Whether this represents a group of patients protected
from airway remodelling or at an earlier stage of the nat-
ural history needs to be further explored.
In contrast to sputum IL-1β, sputum IL1α was not
closely related to neutrophilic inflammation but was
increased in those subjects with low RB1 luminal area
increased and in those subjects with both low RB1 total
area and neutrophilic inflammation. Recent evidence has
implicated IL-1α as an important link between theinnate immune system and allergic sensitisation TLR4
activation induces IL-1α release from epithelial cells,
which acts in an autocrine manner to release GM-CSF
and IL-33 [38]. IL-1α is a potent activator of fibroblasts
[39] and might play a role in fibroblast activation and
hyperplasia in asthma. In atherosclerosis [40] IL-1α has
also been implicated in the plaque stability and outward
vessel remodelling. Whether IL-1α plays a similarly im-
portant role in differential changes in airway geometry
warrants further study.
One major criticism of our study is the cross-sectional
design, which limits our interpretation of the dynamic
relationship between the mediator profiles and airway
remodelling. For example, it is uncertain whether the
changes observed by CT imaging reflect progressive re-
modelling over many years as a consequence of airway
inflammation or represent changes in airway geometry
that were established in early lung development [41].
For example, there were small differences in the age of
onset of disease and current age, albeit not disease dur-
ation, in subjects in the CT defined subgroups. This ef-
fect of time is particularly important when considering
differential mediator profiles between subjects in whom
the airway wall has remodelled towards the airway
Figure 2 Subjects stratified into four groups using the median sputum neutrophil count (≤66% versus >66%) and the RB1 total area
(≤16 mm2/m2 versus >16 mm2/m2) on the X axis, their corresponding sputum levels of A) CCL11 (pg/ml), B) fibrinogen (ng/ml),
C) ICAM (pg/ml) D) IL-1α (pg/ml) and e) IL-1β (pg/ml) on the log transformed Y axis. Bar represents median value, p value by Kruskal
Wallis ANOVA.
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http://respiratory-research.com/content/14/1/17lumen versus those that have either maintained normal
luminal patency or have remodelled away from the
lumen and have airway dilatation. To address this ques-
tion either longitudinal studies of the natural history of
remodelling are required or studies of interventions that
might impact in the short term upon remodelling such
as bronchial thermoplasty [42,43]. Importantly, luminal
area in the severe asthma group is decreased compared
to controls such that even the high luminal area group
described here do not represent bronchial dilatation
compared to health. A further criticism is that sputum
analysis reflects a composite measure of the proximal
airways rather than a specific lobe whereas the CT im-
aging here focussed upon the dimensions of the RB1. Al-
though a more comprehensive volumetric analyses the
entire proximal airway tree would be informative we and
others have reported that the RB1 geometry has good
correlations with other proximal airways [44]. Therefore,we are confident that this is not a major limitation of
this study. The sputum samples were processed with the
mucolytic DTT, which affects the recovery of a number
of mediators in particular Th2 cytokines. The scope of
the mediators measured here are therefore hampered by
this shortcoming, but none the less we have measured a
comprehensive panel of biomarkers and are confident
this reflects many aspects of the inflammatory profile in
the airway of these subjects. Sputum analysis is
restricted to sampling to the airway lumen and does not
necessarily reflect airway inflammation in the airway
wall. Large studies of the relationship between airway
wall remodelling determined by bronchial biopsies and
CT imaging are underway and the findings are eagerly
awaited.
In conclusion, severe asthma is a complex heteroge-
neous disease and the interactions between airway in-
flammation and remodelling are poorly understood.
Figure 3 Subjects stratified into four groups using the median sputum neutrophil count (≤66% versus >66%) and the RB1 luminal
area (≤ 5 mm2/m2 versus >5 mm2/m2) on the X axis, their corresponding sputum levels of A) CCL11 (pg/ml), B) fibrinogen (ng/ml),
C) ICAM (pg/ml) D) IL-1α (pg/ml) and E) MMP-9 (ng/ml) on the log transformed Y axis. Bar represents median value, p value by Kruskal
Wallis ANOVA.
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http://respiratory-research.com/content/14/1/17Here we have demonstrated that sputum mediator pro-
filing reveals a number of associations between airway
geometry and sputum differential cell counts and medi-
ator concentrations. Whether these findings reflect spe-
cific and consistent underlying biological phenotypes
with predictable natural histories and the potential for
stratified medicine approaches needs to be further
investigated.
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